Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer

C. Šálek, P. Mináriková, L. Benešová, V. Nosek, R. Strnad, M. Zavoral, M. Minárik

. 2009 ; 29 (5) : 1803-1810.

Language English Country Greece

Document type Research Support, Non-U.S. Gov't

BACKGROUND: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. PATIENTS AND METHODS: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. RESULTS: The median survival in K-ras positive group was 7.0+/-2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0+/-0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. CONCLUSION: None of the studied molecular markers was identified as an independent factor determining survival prognosis.

000      
03450naa 2200409 a 4500
001      
bmc11019682
003      
CZ-PrNML
005      
20120327145944.0
008      
110714s2009 gr e eng||
009      
AR
035    __
$a (PubMed)19443408
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Šálek, Cyril, $d 1977- $7 xx0098743
245    10
$a Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer / $c C. Šálek, P. Mináriková, L. Benešová, V. Nosek, R. Strnad, M. Zavoral, M. Minárik
314    __
$a Laboratory for Molecular Genetics and Oncology, Genomac International Ltd., Bavorska 856, 15541 Prague 5, Czech Republic.
520    9_
$a BACKGROUND: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. PATIENTS AND METHODS: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. RESULTS: The median survival in K-ras positive group was 7.0+/-2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0+/-0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. CONCLUSION: None of the studied molecular markers was identified as an independent factor determining survival prognosis.
590    __
$a bohemika - dle Pubmed
650    _2
$a alely $7 D000483
650    _2
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 18 $7 D002887
650    _2
$a lidské chromozomy, pár 9 $7 D002899
650    _2
$a geny p53 $7 D016158
650    _2
$a geny ras $7 D011905
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a nádory slinivky břišní $x genetika $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a analýza přežití $7 D016019
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mináriková, Petra $7 xx0054190
700    1_
$a Mináriková, Lucie, $d 1974- $7 xx0105258
700    1_
$a Nosek, Vladimír $7 xx0095912
700    1_
$a Strnad, Robin, $d 1968- $7 xx0061410
700    1_
$a Zavoral, Miroslav, $d 1953- $7 xx0036686
700    1_
$a Minárik, Marek, $d 1970- $7 xx0071043
773    0_
$t Anticancer Research $g Roč. 29, č. 5 (2009), s. 1803-1810 $x 0250-7005 $w MED00000478
910    __
$a ABA008 $b x $y 2
990    __
$a 20110715115251 $b ABA008
991    __
$a 20120327145927 $b ABA008
999    __
$a ok $b bmc $g 864510 $s 729561
BAS    __
$a 3
BMC    __
$a 2009 $b 29 $c 5 $d 1803-1810 $i 0250-7005 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a 2011-3B09/Bjvme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...